Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions ...

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 14 cents per share. The company posted revenue of $170.4 ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The adjustment reflects Vertex's strong performance in its cystic fibrosis (CF) business, which has outperformed expectations. The company's recent financial results have demonstrated the ...

These updates underscore Vertex’s commitment to addressing the underlying causes of serious kidney diseases and expanding its pipeline in renal medicine. The company is also progressing in other ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, released new innovations, honored partners and ...

which may reflect concerns about the company’s ability to continue operations. Vertex has advantages when competing with Bluebird. In my view, the medicine has superior pricing and a superior ...

It’s been a busy few years for 32-year-old Oliver Smith. After leaving school, he honed his carpentry skills before moving to ...